1.	Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016924, COU-AA-301, NCT00638690
2.	Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase III Type: Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: CR016927, COU-AA-302, 2008-008004-41, NCT00887198
3.	Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016969, COU-AA-002, NCT00473746
4.	A Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016915, COU-AA-003, NCT00474383
5.	A Study of Abiraterone Acetate and Prednisone in Patients With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016921, COU-AA-004, NCT00485303
6.	An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016906, COU-AA-BMA, NCT00544440
7.	A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016936, COU-AA-201, NCT00924469
8.	Abiraterone Acetate, Prednisone, and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 7048, NCI-2009-01346, P30CA015704, NCT01023061
9.	Abiraterone Post Ketoconazole for Prostate Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CC# 085514, NCT01199146
10.	Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-448, NCT01393730
11.	A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018715, 212082PCR2008, NCT01424930
12.	Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: Not specified Sponsor: Pharmaceutical / Industry Protocol IDs: GO27983, 2011-004126-10, NCT01485861
13.	Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: P11-3, NCT01487863
14.	A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR017062, JNJ-212082-JPN-202, NCT01795703
15.	Abiraterone Acetate in Patients With Prostate Cancer Who Have Failed Hormone Therapy Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: CR016909, COU-AA-001, NCT00473512
16.	A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016942, COU-AA-006, NCT00910754
17.	A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR017128, COU-AA-015, NCT01017939
18.	Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR017137, JNJ-212082-JPN-102, NCT01186484